Trial Profile
A retrospective study of clinical characteristics of immune-related liver injury induced by ICIs to find out predictive markers in Japanese patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Oct 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Gastric cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Malignant-mesothelioma; Non-small cell lung cancer; Renal cell carcinoma
- Focus Adverse reactions
- 27 Oct 2021 New trial record